zolbetuximab
astellas
[]
asco gi 2023: spotlight has brightened the light : zolbetuximab+mfolfox6 shows benefit in os as 1l cldn18.2-high expressing goj/gc tumors &gt; new predictive biomarker to implement in our clinical practice to find this subset of patients 